This week's round-up of new financings in the biotech world is headed by a big round for Third Arc, a specialist in T-cell engager antibodies, with Autobahn, Brenig, Confo, and GRO Bio also
In a letter to the new UK Prime Minister Keir Starmer, leading figures in industry and academia have called for a plan to turn the Oxford-Cambridge region into the 'crown jewel' of the nati
Patient recruitment remains a significant challenge for biopharma companies, often leading to delays and increased costs in clinical trials.
Vaccination with GSK's recombinant shingles vaccine, Shingrix, could delay the onset of dementia, according to researchers in the UK.
FDA reviewers were so frustrated by AstraZeneca's application for Imfinzi as a treatment before and after surgery for resectable non-small cell lung cancer (NSCLC) that they voted for a ret
Editor's Picks
